HLB (Holding Companies) Overview
- Year Founded
-
1975
- Status
-
Public
- Employees
-
157
- Stock Symbol
-
028300
- Investments
-
21
- Share Price
-
$21.01
- (As of Monday Closing)
HLB (Holding Companies) General Information
Description
HLB Co Ltd is engaged in the manufacture of lifeboats, special ships, safety goods, and engines. It is also engaged in pipe business and bio-technology business.
Contact Information
Website
www.hlbkorea.comCorporate Office
- 10-5, Myeonghaksandanseo-ro
- Yeondong-myeon
- Sejong, 30068
- South Korea
Corporate Office
- 10-5, Myeonghaksandanseo-ro
- Yeondong-myeon
- Sejong, 30068
- South Korea
HLB (Holding Companies) Stock Performance
As of 16-Nov-2026, HLB (Holding Companies)’s stock price is $21.01. Its current market cap is $2.79B with 133M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.01 | $21.40 | $16.12 - $48.24 | $2.79B | 133M | 1.15M | -$0.82 |
HLB (Holding Companies) Financials Summary
As of 30-Sep-2026, HLB (Holding Companies) has a trailing 12-month revenue of $69.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,305,740 | 4,773,396 | 6,537,459 | 5,044,771 |
| Revenue | 69,429 | 59,146 | 49,930 | 32,812 |
| EBITDA | (94,506) | (158,338) | (69,983) | (152,403) |
| Net Income | (108,603) | (154,940) | (67,413) | (143,445) |
| Total Assets | 656,975 | 645,953 | 602,473 | 579,674 |
| Total Debt | 236,606 | 197,877 | 108,631 | 48,625 |
HLB (Holding Companies) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HLB (Holding Companies) Patents
HLB (Holding Companies) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020227591-A1 | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition | Active | 28-Feb-2019 | ||
| AU-2020227591-B2 | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition | Active | 28-Feb-2019 | ||
| EP-3932936-A1 | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition | Pending | 28-Feb-2019 | ||
| EP-3932936-A4 | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition | Pending | 28-Feb-2019 | ||
| US-12371453-B2 | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition | Active | 28-Feb-2019 | C07K7/06 |
HLB (Holding Companies) Signals
HLB (Holding Companies) Investments & Acquisitions (21)
HLB (Holding Companies)’s most recent deal was a PIPE with HLB Pep for . The deal was made on 10-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HLB Pep | 10-Mar-2025 | PIPE | Drug Discovery | ||
| HLB Pep | 10-Mar-2025 | Merger/Acquisition | Drug Discovery | ||
| HLB Genex | 12-Dec-2024 | PIPE | Drug Discovery | ||
| HLB Therapeutics | 01-Apr-2024 | PIPE | Drug Discovery | ||
| Jiangsu Hengrui Pharmaceuticals (Global rights of Camrelizumab) | 06-Mar-2024 | Corporate Asset Purchase | Buildings and Property |
HLB (Holding Companies) ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
22.25 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Supplies
Subindustry
of 60
Rank
Percentile
HLB (Holding Companies) Exits (1)
HLB (Holding Companies)’s most recent exit was on 27-Apr-2021 from Verismo Therapeutics. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Verismo Therapeutics | 27-Apr-2021 | Completed |
|
HLB (Holding Companies) Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| HLB Investment | Seoul, South Korea | 2021 | |
| HLB bioStep Company | Incheon, South Korea | 2012 | |
| Elevar Therapeutics | Fort Lee, NJ | 2005 | |
| HLB Pep | Jeonnam-Gwangju, South Korea | 2000 | |
| Corki | Seoul, South Korea |
HLB (Holding Companies) FAQs
-
When was HLB (Holding Companies) founded?
HLB (Holding Companies) was founded in 1975.
-
Where is HLB (Holding Companies) headquartered?
HLB (Holding Companies) is headquartered in Sejong, South Korea.
-
What is the size of HLB (Holding Companies)?
HLB (Holding Companies) has 157 total employees.
-
What industry is HLB (Holding Companies) in?
HLB (Holding Companies)’s primary industry is Holding Companies.
-
Is HLB (Holding Companies) a private or public company?
HLB (Holding Companies) is a Public company.
-
What is HLB (Holding Companies)’s stock symbol?
The ticker symbol for HLB (Holding Companies) is 028300.
-
What is the current stock price of HLB (Holding Companies)?
As of 16-Nov-2026 the stock price of HLB (Holding Companies) is $21.01.
-
What is the current market cap of HLB (Holding Companies)?
The current market capitalization of HLB (Holding Companies) is $2.79B.
-
What is HLB (Holding Companies)’s current revenue?
The trailing twelve month revenue for HLB (Holding Companies) is $69.4M.
-
What is HLB (Holding Companies)’s annual earnings per share (EPS)?
HLB (Holding Companies)’s EPS for 12 months was -$0.82.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process